SNPMiner Trials by Shray Alag


SNPMiner Trials: SNP Report

Report for SNP rs4848306

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Genetic Polymorphisms Associating With CAD, Inflammatory Biomarkers, and Oxidized Phospholipids in a Greek Population

The design and purpose of the current study is to expand and validate previous findings that the IL-1 gene cluster composite genotype patterns potentiate the risk for coronary artery disease (CAD) and cardiovascular events mediated by OxPL and Lp(a). A secondary objective is to validate other, non IL-1 genetic variants associated with CAD.

NCT02307422 Coronary Artery Disease Genetic: IL-1 Genotypes, other SNPs associated with CAD
MeSH: Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO: Coronary artery atherosclerosis

quartiles) of LP(a) and specific oxidized phospholipids among diabetic and non-diabetic subjects.. Evidence of IL-1 risk genotypes of the PerioPredict Test in relation to levels of Lp(a)(mg/dL) and oxPL/apoB (RLU) in CAD patients.. Compare the frequencies of positive and negative genetic test results (PerioPredict Test, composite genotype of rs16944, rs1143623, rs4848306, rs1143633)among CAD patients based on previously collected levels (eg.

Primary Outcomes

Description: Compare the frequencies of positive and negative genetic test results (Heart Health Test, composite genotype of rs17561, rs1143634, rs16944) among CAD patients based on previously collected levels (eg. quartiles) of LP(a) and specific oxidized phospholipids among diabetic and non-diabetic subjects.

Measure: Evidence of IL-1 risk genotypes of the Heart Health Test in relation to levels of Lp(a)(mg/dL) and oxPL/apoB (RLU) in CAD patients.

Time: Approximately 1 year

Secondary Outcomes

Description: Compare the frequencies of positive and negative genetic test results (PerioPredict Test, composite genotype of rs16944, rs1143623, rs4848306, rs1143633)among CAD patients based on previously collected levels (eg. quartiles) of LP(a) and specific oxidized phospholipids among diabetic and non-diabetic subjects.

Measure: Evidence of IL-1 risk genotypes of the PerioPredict Test in relation to levels of Lp(a)(mg/dL) and oxPL/apoB (RLU) in CAD patients.

Time: Approximately 1 year

Description: Compare the frequencies of SNP alleles, haplotypes, and composite genotypes among CAD patients based on levels (eg. quartiles) of LP(a) in mg/dL and oxidized phospholipids/apoB (RLU) among diabetic to non-diabetic subjects.

Measure: Evidence for other non IL-1 gene SNPs, previously shown to be associated with CAD, in relation to levels of Lp(a)(mg/dL) and oxPL/apoB (RLU) among diabetic and non-diabetic patients.

Time: Approximately 1 year

HPO Nodes

Coronary artery atherosclerosis
Genes 34
TGFB2 TGFB3 TGFBR1 LDLRAP1 TGFBR2 MFAP5 APOA1 APOB ABCA1 MYH11 ELN LIPC FBN1 PRKG1 APOE PPARG ZMPSTE24 MYLK LMNA CYP7A1 SERPIND1 LDLR LOX MAT2A ABCG5 ABCG8 KCNJ5 ESR1 ZNF687 SMAD3 PCSK9 CEP19 ACTA2 FOXE3